Research Article

Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients

Table 2

Comparison of laboratory findings between COVID-19 cases receiving two types of therapeutics.

FeaturesTrendLopinavir/ritonavir
(%)
Atazanavir/ritonavir
(%)
value

WBC on admissionNo change42 (55.3)34 (44.7)0.127
Increasing11 (42.3)15 (57.7)
Decreasing1 (16.7)5 (83.3)
HbNo change51 (51)49 (49)0.554
Increasing0 (0)1 (100)
Decreasing3 (42.9)4 (51.7)
PlateletNo change35 (48.6)37 (51.4)0.906
Increasing4 (50)4 (50)
Decreasing15 (53.6)13 (46.4)
Lymphocyte countNo change37 (54.4)31 (45.6)0.478
Increasing16 (41.2)26 (57.9)
Decreasing1 (50)1 (50)
ESRNo change19 (46.3)22 (53.7)0.836
Increasing34 (52.3)31 (47.7)
Decreasing1 (50)1 (50)
CRPNo change21 (50)21 (50)0.587
Increasing32 (51.6)30 (48.4)
Decreasing1 (25)3 (75)
CreatinineNo change42 (50.6)41 (49.4)0.82
Increasing12 (48)13 (52)
ASTNo change36 (49.3)37 (50.7)0.978
Increasing17 (51.5)16 (48.5)
Decreasing1 (50)1 (50)
ALTNo change42 (53.8)36 (46.2)0.423
Increasing11 (40.7)16 (59.3)
Decreasing1 (33.3)2 (66.7)
ALPNo change47 (48.5)50 (51.5)0.579
Increasing6 (66.7)3 (33.3)
Decreasing1 (50)1 (50)
BilirubinNo change47 (78.3)13 (21.7)<0.001
Increasing7 (14.6)41 (85.4)
Lipid profileNo change38 (47.5)42 (52.5)0.380
Increasing16 (57.1)12 (42.9)
BSNo change41 (53.2)36 (46.8)0.288
Increasing13 (41.9)18 (58.1)
CPKNo change36 (49.3)37 (50.7)0.790
Increasing17 (53.1)15 (46.9)
Decreasing1 (33.3)2 (66.7)
LDHNo change37 (50.7)36 (49.3)0.841
Increasing16 (50)16 (50)
Decreasing1 (33.3)2 (66.7)
INRNo change50 (52.6)45 (47.4)0.139
Increasing4 (30.8)9 (69.2)

ALP: alkaline phosphatase; ALT: alanine amino transaminase; AST: aspartate amino transaminase; BS: blood sugar; CBC: complete blood count; CPK: creatinine phosphokinase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; Hb: hemoglobin; INR: international normalized ratio; LDH: lactate dehydrogenase; WBC: white blood cell. Bold value indicates statistical significance.